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Abstract: The hominid SINE-VNTR-Alu (SVA) retrotransposons represent a repertoire of genomic 
variation which could have significant effects on genome function. A human-specific SVA in the 
promoter region of the gene leucine-rich repeats and immunoglobulin-like domains 2 (LRIG2), 
which we termed SVA_LRIG2, is a common retrotransposon insertion polymorphism (RIP), defined 
as an element which is polymorphic for its presence or absence in the genome. We hypothesised 
that this RIP might be associated with differential levels of expression of LRIG2. The RIP genotype 
of SVA_LRIG2 was determined in a subset of frontal cortex DNA samples from the North American 
Brain Expression Consortium (NABEC) cohort and was imputed for a larger set of that cohort. 
Utilising available frontal cortex total RNA-seq and CpG methylation data for this cohort, we 
observed that increased allele dosage of SVA_LRIG2 was non-significantly associated with a 
decrease in transcription from the region and significantly associated with increased methylation of 
the CpG probe nearest to SVA_LRIG2, i.e., SVA_LRIG2 is a significant methylation quantitative trait 
loci (mQTL) at the LRIG2 locus. These data are consistent with SVA_LRIG2 being a transcriptional 
regulator, which in part may involve epigenetic modulation. 
Keywords: SVA; polymorphism; retrotransposon; gene regulation; LRIG2; evolution; RIP; 
retrotransposon insertional polymorphism 
 
1. Introduction 
Across many diseases, most disease-associated genetic variation identified by genome-wide 
association studies and gene candidate studies is located within non-coding DNA. A major 
constituent of non-coding DNA is sequence derived from retrotransposons, which constitute 
approximately 45% of the human genome [1]. Retrotransposon sequences propagate throughout the 
genome via a ‘copy-and-paste’ mechanism, first involving transcription into RNA followed by 
reverse transcription and insertion of a new copy at a distant genomic site. They are important 
contributors to genetic diversity via their ability to introduce novel splice sites, promoters and 
regulatory elements into a locus [2,3], thus facilitating the generation of novel species- and tissue-
specific expression patterns in the germline. 
Non-long terminal repeat (non-LTR) retrotransposons are the only known contemporarily active 
retrotransposons in the human genome, of which SINE-VNTR-Alu (SVA) elements are the 
evolutionarily youngest [1]. Present only in hominids, there are approximately 3000 identified in the 
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reference human genome (Hg38). Considered 5′ to 3′, SVAs are composed of a CT element (CCCTCTn 
repeat), an antisense Alu-like (another retrotransposon family) sequence, one or two variable number 
tandem repeat (VNTR) regions, a short interspersed nuclear element (SINE) region derived from the 
retroviral HERV-K10 element, and a poly-A tail [4] (Figure 1). SVAs do not transpose autonomously 
but are mobilised in trans by the transposition machinery of LINE-1, an autonomous class of non-
LTR retrotransposon [5]. Full-length SVAs vary from 1 to 4 kb in size, and are classified A–F in order 
of evolutionary age based on their SINE region [4]. Additionally, an F1 class of SVA contains a 5′ 
transduction of exon 1 of the MAST2 gene [6], such that much or all of the CT element is replaced 
(Figure 1). SVA subfamilies E, F and F1 are human specific, and with the addition of the D subfamily, 
are transpositionally active within the human genome [4]. It is estimated that one novel SVA insertion 
event occurs every 916 births, corresponding to 7 × 106 distinct insertions worldwide [7]. A genomic 
site where a retroelement may be present or absent is known as a retrotransposon insertion 
polymorphism (RIP), and the average human is estimated to possess 56 SVA RIPs that differ from 
the reference genome [8]. Additionally, SVAs may be polymorphic with regards to the length (repeat 
copy number) of their CT element, VNTR and poly-A signal components, and may also contain 
single-nucleotide polymorphisms (SNPs). Accordingly, SVAs are considered the most polymorphic 
structural variants in the genome [8]. 
 
Figure 1. The canonical structure of the SVA F1 retrotransposon subclass, 5′ to 3′ displayed left to 
right. Purple: 5′ transduction of exon 1 of MAST2. Potential CCCTC-binding factor (CTCF) binding 
site and CpG island are displayed. Orange: The (CCCTCT)n hexamer repeat, which may be variable 
in copy number. Note, much of this sequence has been replaced by the MAST2 transduction. Blue: 
The Alu-like region, which is composed of two antisense Alu regions separated by a small intervening 
sequence. Green: The VNTR region which may be one or two regions of 35–50 bp tandem repeats, 
and may reach GC content of 70%. A CpG island is pictured, with black lollipops signifying 5-
methylcytosine residues. A potential binding site for CTCF is shown. Grey: The SINE region is 
derived from the 3′ LTR of the retroviral HERV-K10 element. Red: The canonical polyadenylated tail 
can act as a signal for transcription termination but may be bypassed by RNA polymerase, and is 
thought to be important for SVA retrotransposition. Black arrowheads indicate target site duplication 
regions resulting from insertion. 
On chromosome 1, there is a 2.4 kb long (full-length) SVA F1 positioned approximately 2 kb 
upstream from the transcriptional start site of leucine-rich repeats and immunoglobulin-like domains 
2 (LRIG2) (Figure 2), a protein which is involved in epidermal growth factor signalling. The LRIG2 
protein is ubiquitously expressed but deleterious mutations are associated with urofacial syndrome 
[9,10], a disorder characterised by improper nerve control of the face and bladder [11]. LRIG2 shares 
its bidirectional promoter region with a non-coding divergent transcript, LRIG2-DT, whose 
expression could be similarly regulated [12–14] (Figure 2). The SVA proximal to this LRIG2 locus 
(herein SVA_LRIG2) is a RIP, meaning that it transposed relatively evolutionarily recently, and may 
represent an insertion event involved in human-specific modulation of gene expression. Indeed, SVA 
RIPs and length polymorphisms may have profound effects on gene regulation and genomic 
architecture. Over 60% of SVAs in the reference genome are found in genes or within 10 kb of a gene 
despite this representing only approximately 1% of the human genome [15], suggesting preferential 
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insertion into actively transcribed regions [4]. The GC content of an SVA is approximately 60% and 
may exceed 70% within the VNTR region, satisfying the definition of a CpG island [16]. SVAs have 
been shown to be methylated in somatic tissue, with evolutionarily older classes of SVA generally 
showing greater methylation [17]. DNA methylation is known to be capable of spreading laterally 
along DNA from CpG islands [18], and mouse B1 SINE retrotransposons have been shown to induce 
transcriptional repression by DNA methylation spreading [19]. An SVA insertion may therefore 
influence expression of nearby genes by altering local chromatin structure or recruiting factors 
depending on both the SVA’s primary sequence and epigenetic marks [20,21]. Indeed, the 5′ MAST2 
exon 1 transduction associated with SVA F1 elements is defined as a CpG island and has been 
demonstrated to influence transcription in human germline cells [22]. SVAs may also influence 
chromatin structure by recruiting CCCTC-binding factor (CTCF), a master regulator of 3D chromatin 
structure [23]. It has been demonstrated that CTCF can bind the SVA VNTR region in vitro, while the 
germline-expressed paralog CTCF like (CTCFL, also referred to as BORIS) can bind the VNTR region 
in vivo [21]. Interestingly, CTCFL has also been shown to bind immediately upstream of the SVA F1 
subfamily [21]. 
 
Figure 2. (a) The LRIG2 locus as shown on UCSC genome browser hg38, displaying two validated 
LRIG2 isoforms and first exon of LRIG2-DT from the RefSeq genes curated subset, and the LRIG2 
promoter-associated CpG island. SVA_LRIG2 position is displayed. (b) Regions flanking SVA_LRIG2 
are displayed, with distance to LRIG2 locus transcriptional start sites highlighted in red. Distance 
between LRIG2 and LRIG2-DT transcriptional start sites highlighted in orange. 
Reporter gene studies have demonstrated that gene expression was differently modulated by 
different SVA components and the full-length SVA both in vitro and in vivo [15,24]. Indeed, genomic 
VNTRs have previously been shown to represent regions of stimulus responsive histone marks [25]. 
It should come as no surprise that insertion of SVAs into open reading frames is directly causative of 
at least 12 diseases due to transcriptional interference [26]. It is interesting to note that in X-linked 
Dystonia-Parkinsonism not only does a disease-specific SVA insertion appear causative of disease, 
but that the length of the CT hexamer repeat strongly correlates inversely with age of onset of the 
disease [27,28]. 
It is clear that SVAs represent non-coding DNA elements that have the potential to exert potent 
regulatory influences on nearby gene expression, and that RIPs or length polymorphisms between 
individuals may contribute to interpersonal differences in expression patterns. However, most work 
on SVAs thus far focus on their properties in vitro or in disease; there is currently a scarcity of data 
on the functional influence that SVAs may have in normal gene regulation in humans in situ. 
SVA_LRIG2 represents an opportunity to study the influence of an SVA insertion in situ as it is a RIP, 
(a) 
(b) 
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meaning that DNA samples from the general populace represent a naturally occurring resource to 
address the influence of presence or absence of an SVA on genome structure or gene regulation. 
Indeed, the Database of RIPs in Humans (dbRIP) assigns an allele frequency of 0.422 to the presence 
of SVA_LRIG2 (dbRIP accession RIP3000013) [29], meaning that presence and absence of the SVA 
should be observed almost equally often. Furthermore, SVA_LRIG2 has a GC content of 
approximately 70% and contains 170 CpG dinucleotides, representing a potentially substantial CpG 
island. By contrast, the CpG island associated with the LRIG2 promoter region, identified in the UCSC 
genome browser, is 669 bp long, approximately 65% GC content and contains 57 CpGs (Figure 2). We 
might postulate that this CpG island would be sensitive to methylation changes induced by the much 
larger one represented by SVA_LRIG2. To investigate the potential for this RIP to exert regulatory 
properties at the LRIG2 locus we genotyped SVA_LRIG2 in DNA samples from the North American 
Brain Expression Consortium (NABEC), a cohort of neurologically normal frontal cortex samples 
from the Database of Genotypes and Phenotypes (dbGaP) for which molecular datasets including 
genome-wide genotyping, total RNA sequencing and CpG methylation were available. 
2. Results 
2.1. SVA_LRIG2 Genotypes Were PCR Validated or Imputed for 288 Individuals 
Although the NABEC cohort has undergone whole-genome sequencing (WGS), repetitive DNA 
elements such as retrotransposons are routinely filtered out due to their inherent difficulties in 
mapping back to the reference genome [30]. It was therefore necessary to genotype SVA_LRIG2 in 
the available samples from the NABEC cohort. Ninety-six brain DNA samples underwent PCR with 
forward and reverse primers that annealed 1.1 kb upstream and 0.8 kb downstream of genomic 
SVA_LRIG2, respectively. The inclusion of these flanking regions yielded a 1.9 kb PCR product when 
SVA_LRIG2 was absent from the locus and an approximately 4.3 kb PCR product when the SVA was 
present (Figure 3). This production of two distinctly sized PCR fragments allowed SVA RIP genotype 
(presence or absence) to be readily determined following agarose gel electrophoresis and 
visualisation. A representative gel is shown in Figure 3. Of the 96 samples genotyped, 14 had no 
copies of SVA_LRIG2 present at the locus (−/−), 43 had 1 copy present (+/−, i.e., the SVA was present 
on a single chromosome) and 39 had 2 copies present (+/+, i.e., the SVA was present on both 
chromosomes) (Table 1). 
Although repetitive elements are not typically included in WGS processing and genotype 
calling, it is assumed that these variants may occur within haplotype blocks shared with variants 
through linkage disequilibrium. Therefore, the genotypes of these typically uncalled variants of 
interest may be inferred through ‘proxy’ (or ‘tagging’) SNPs that are in linkage disequilibrium [31]. 
In this way the genotype of SVA_LRIG2 can be imputed in NABEC individuals whose DNA was not 
available in our lab. We observed that SVA_LRIG2 exhibited length polymorphism with 4 VNTR 
alleles and developed proxy SNPs for each of them in order to fully capture the genetic diversity of 
SVA_LRIG2. This produced a total of 29 proxy SNPs, and the SNP with highest linkage 
disequilibrium r2 and D’ value for each VNTR allele was taken forward (see Materials and Methods). 
VNTR allele 4 was excluded after filtering for standard genotype missingness. The chosen proxy 
SNPs recapitulated the 96 PCR-validated genotypes with 97.4% accuracy (187 out of 192 alleles, data 
not shown). We then grouped these alleles into SVA_LRIG2 RIP genotypes: −/−, +/− and +/+. When 
added to the existing validated genotyping, this yielded 49 SVA_LRIG2 −/− genotypes, 154 
SVA_LRIG2 +/− and 85 SVA_LRIG2 +/+, for a total of 288 individuals (Table 1). 
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Figure 3. Representative image of NABEC DNA samples following PCR with primers targeting 
regions flanking SVA_LRIG2. A 1.9 kb PCR product corresponds to SVA_LRIG2 being absent from 
the locus and a 4.3 kb PCR product corresponds to SVA_LRIG2 presence. Sample genotypes are 
displayed along the bottom. NTC = Non-template control. Red asterisk indicates formation of non-
specific PCR products of approximately 1.5 kb. 
Table 1. SVA_LRIG2 RIP genotype counts in NABEC samples. 
SVA_LRIG2 Genotype Validated Counts Imputed Counts Total Counts 
−/− 14 35 49 
+/− 43 111 154 
+/+ 39 46 85 
Total 96 192 288 
2.2. Increased Allele Dosage of SVA_LRIG2 Is Non-Significantly Associated with Reduced Transcription 
from the LRIG2 Locus 
Having determined SVA_LRIG2 RIP genotypes experimentally or computationally, we assessed 
whether these genotypes correlated with transcription at the LRIG2 locus. Of the 288 individuals in 
NABEC with validated or imputed SVA_LRIG2 genotypes, frontal cortex total RNA-seq data were 
available for 229. Expression values, expressed as quantile normalised transcripts per kilobase million 
(TPM), were extracted for LRIG2 and LRIG2-DT. These expression values were stratified on the basis 
of SVA_LRIG2 RIP genotype, resulting in 34 individuals of the genotype SVA_LRIG2 −/−, 104 that 
were SVA_LRIG2 +/− and 91 that were SVA_LRIG2 +/+. Compared to those with no copies of 
SVA_LRIG2 (−/−), individuals with the RIP genotype SVA_LRIG2 +/− displayed a median expression 
of LRIG2 that was 0.390 standard deviations lower and those with SVA_LRIG2 +/+ were 0.443 lower 
in the quantile normalised data (Figure 4a). Similarly, median expression of LRIG2-DT was 0.451 
standard deviations lower in SVA_LRIG2 +/− individuals and 0.228 lower in SVA_LRIG2 +/+ 
individuals compared to those of genotype −/− (Figure 4b). A simple linear regression was used to 
assess whether SVA_LRIG2 was an expression quantitative trait loci in neurologically normal brain, 
i.e., whether increasing allele dosage of SVA_LRIG2 correlated with differential expression of LRIG2 
or LRIG2-DT in the NABEC RNA-seq data. The linear regression model included the known 
covariates age, gender, ethnicity, originating brain bank and RNA integrity number. Alpha 
significance level was set at 2.94E-3 using Bonferroni correction for multiple comparisons (see Section 
4). Although we found that SVA_LRIG2 RIP genotype was not significantly associated with 
expression of LRIG2 or LRIG2-DT (Figure 4, p = 0.190 and p = 0.477, respectively), our model indicated 
a negative trend between SVA_LRIG2 allele dosage and expression of both transcripts (Figure 4, 
negative coefficient values). 





Figure 4. Frontal cortex total RNA-seq data for LRIG2 (ENSG00000198799.12) and LRIG2-DT 
(ENSG00000238198.2) in 229 NABEC individuals grouped by SVA_LRIG2 RIP genotype. A total of 96 
genotypes were PCR validated and 145 were imputed for a total of 241 genotypes. (a) LRIG2 
expression. (b) LRIG2-DT expression. RNA-seq data expressed as quantile normalised transcripts per 
kilobase million (TPM). Standard deviations from the mean of the normalised data are displayed on 
the y-axis. Linear regression analysis is shown, reporting p value of association analysis (P), model 
coefficient and standard error (SE). Outlier value is marked in red. 
2.3. Increased Allele Dosage of SVA_LRIG2 Is Associated with Increased Methylation of the Nearest 450K 
Methylation Probe, cg23932873 
SVAs may simplistically be thought of as mobile CpG islands and DNA methylation is known 
to spread along adjacent DNA [16,18]. Therefore, we determined whether SVA_LRIG2 RIP genotypes 
might be associated with differences in methylation at the locus. Frontal cortex 450K CpG 
methylation data were available for 165 of the 288 individuals in NABEC with validated or imputed 
SVA_LRIG2 genotypes. Methylation data were again stratified on the basis of SVA_LRIG2 RIP 
genotype, resulting in 21 individuals of the genotype SVA_LRIG2 −/−, 78 that were SVA_LRIG2 +/− 
and 66 that were SVA_LRIG2 +/+. Publicly available ENCODE Methylation 450K Bead Array data list 
15 CpG methylation probes in a 20 kb window around SVA_LRIG2, of which 13 are less than 3 kb 
away from the LRIG2 promotor region (probes listed in Materials and Methods). As with the 
expression data, linear regression was used to determine whether SVA_LRIG2 was a methylation 
QTL (mQTL) for these 15 probes, i.e., whether increasing allele dosage of SVA_LRIG2 correlated with 
changes in CpG methylation. The linear regression model included the known covariates age, gender, 
ethnicity and originating brain bank. After Bonferroni correction for multiple comparisons (see 
Section 4), only the CpG dinucleotide probe nearest to SVA_LRIG2, cg23932873, was found to pass 
the adjusted alpha level of 2.94E-3 when methylation was correlated against SVA_LRIG2 genotype 
(Figure 5a). Compared to individuals with the genotype SVA_LRIG2 −/−, the median proportion of 
cg23932873 that was methylated was found to be 0.028 (2.8%) higher in those with the genotype +/− 
and 0.055 (5.1%) higher in those with SVA_LRIG2 genotype +/+ (Figure 5b). Our linear regression 
model provided a p value of 5.1E-4 and coefficient of 0.022, indicating that there is a significant 
association between SVA_LRIG2 allele dosage and increasing methylation of cg23932873. In other 
words, SVA_LRIG2 is a significant mQTL for a CpG dinucleotide at the LRIG2 locus. 





Figure 5. (a) The LRIG2 promoter region as displayed on UCSC genome browser hg38, with two 
validated LRIG2 isoforms and first exon of LRIG2-DT shown by the RefSeq genes curated subset. The 
position of SVA_LRIG2 is displayed in black. The position of cg23932873, the CpG probe closest to 
SVA_LRIG2, is shown in black and the LRIG2 promoter-associated CpG island is shown in green. The 
distances in base pairs from cg23932873 to SVA_LRIG2 and the CpG island are shown in red. (b) 
Frontal cortex CpG 450K methylation data for probe cg23932873 in 184 NABEC individuals grouped 
by SVA_LRIG2 RIP genotype. A total of 96 genotypes were PCR validated and 88 were imputed for 
a total of 184 genotypes. 
2.4. Increased Methylation of cg23932873 Is Weakly Correlated with Decreased Expression of LRIG2 
DNA methylation is known to generally repress gene expression through mechanisms including 
impairment of transcription factor binding and recruitment of proteins that confer repressive histone 
modifications [20]. Therefore, having observed that increased SVA_LRIG2 allele dosage is associated 
with decreased transcription from the LRIG2 locus and increased methylation proximal to 
SVA_LRIG2, we hypothesised that the two may be correlated. Both RNA-seq data for LRIG2 and CpG 
methylation data were available for 118 samples in the NABEC cohort after removal of outliers, while 
119 samples were available for LRIG2-DT expression. CpG beta values for cg23932873 were plotted 
against normalised TPM values for LRIG2 or LRIG2-DT and tested with Pearson correlation 
coefficient. We observed a weak yet significant inverse correlation between cg23932873 methylation 
and LRIG2 expression (Figure 6a), and no correlation between cg23932873 methylation and LRIG2-
DT expression (Figure 6b). 
 




Figure 6. Expression of transcripts from the LRIG2 locus versus CpG 450K methylation data for probe 
cg23932873 in frontal cortex of 129 NABEC individuals. (a) LRIG2 (ENSG00000198799.12). (b) LRIG2-
DT (ENSG00000238198.2). Blue line indicates trend line; dark grey zone indicates 95% confidence 
interval. Pearson correlation coefficient and corresponding p values displayed. 
3. Discussion 
Despite transposable elements making up nearly half of the human genome, they remain 
relatively unexplored as sources of important genomic variation [1], as their repetitive nature makes 
them difficult to map to the human genome. The evolutionarily youngest SVA retrotransposons may 
be particularly important for human health and evolution since they have introduced hominid-
specific elements with regulatory potential to specific genomic loci, a process that is ongoing for SVA 
subclasses D–F1 [32]. It should be noted that SVA regulatory influences need not be dramatic to be 
biologically important in individuals of certain genetic backgrounds—for example, in the study of 
genetically complex disease, it is generally accepted that disease can result from the cumulative effect 
of many low-contribution variants [33]. Here we have investigated how presence or absence of an 
SVA retrotransposon 2 kb upstream of a divergent promoter region might influence regulation of 
transcription. SVA_LRIG2 is a relatively common RIP, meaning that the general populace represents 
a ready-made resource of the potential effects of SVA_LRIG2 presence vs absence at the LRIG2 locus. 
The RIP genotype of SVA_LRIG2 was determined in the NABEC cohort using PCR and imputation 
and correlated with both gene expression and methylation at the nearby LRIG2 and LRIG2-DT 
promoter region. 
We observed a negative correlation between increased SVA_LRIG2 allele dosage and 
transcription of both LRIG2 and the region’s divergent transcript LRIG2-DT in our linear regression 
models, but this did not achieve statistical significance. However, we note that this is not unexpected 
in a relatively small study of a heterogeneous population. Furthermore, the frontal cortex samples 
represent a tissue of heterogeneous cell types including neurons and glial cells, which may act to 
convolute expression and methylation patterns. Additionally, in this study, the SVA_LRIG2 
genotype −/− is made up of a considerably fewer samples than genotypes +/− or +/+, and we speculate 
that expression differences may achieve statistical significance with an increased sample/cohort size. 
We postulate that this may be the case for LRIG2 expression in particular, which displayed the clearest 
association between SVA_LRIG2 allele dosage and transcription. Despite falling short of statistical 
significance, these observations suggest that insertion of SVA_LRIG2 near to the LRIG2 promoter 
region may be associated with decreased expression of transcripts from the locus, particularly LRIG2. 
That the two transcripts were similarly affected supports previous models in which divergent 
transcripts were co-regulated [12–14], and suggests a largely orientation-independent model for 
transcriptional modulation by SVA_LRIG2 at this locus. 
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When assessing the 15 CpG methylation probes in the region surrounding SVA_LRIG2, only the 
closest probe, cg23932873, was found to be a significant mQTL. Specifically, we found a strong 
positive association between SVA_LRIG2 allele dosage and levels of methylation of cg23932873 in 
the frontal cortex of individuals from the NABEC cohort. This indicates that SVA_LRIG2 may induce 
increased methylation of cg23932873, potentially via lateral spread of methylation from the GC- and 
CpG-rich SVA [16,18]. Furthermore, when expression from the LRIG2 locus was compared directly 
to methylation of cg23932873 we observed a weak but significant inverse correlation, suggesting that 
increased methylation at cg23932873 induced by SVA_LRIG2 might contribute to the observed 
decrease in expression from the LRIG2 locus. It has been demonstrated that methylated CpG 
dinucleotides are recognised by proteins associated with transcriptional repressor complexes [34], 
and that DNA methyltransferases can cooperate with enzymes that add methylation or remove 
acetylation at histones [35–37]. In this way, increased methylation at cg23932873 resulting from 
SVA_LRIG2 might contribute to formation of a transcriptionally repressive environment at the LRIG2 
locus, leading to the modest modulation of LRIG2 and LRIG2-DT expression we have observed here. 
We note that transcriptionally repressive effects of SVA_LRIG2 may also be mediated by other 
properties of SVA F1s that are not necessarily mutually exclusive to increasing local methylation. For 
example, binding of the chromatin structural regulator CTCF/CTCFL to SVA_LRIG2, either within 
the VNTR or upstream of the MAST2 transduction [21], may form novel chromatin loops that 
preclude interactions between the LRIG2/LRIG2-DT promoter region and enhancer elements [23]. 
However, only expression and methylation datasets were available in the NABEC cohort, meaning 
that analysis of the influence of SVA_LRIG2 on 3D chromatin structure is currently beyond the scope 
of this study. We also note that LRIG2 and LRIG2-DT may be differently affected, particularly at the 
post-transcriptional level, by SVA_LRIG2 owing to its genomic context; SVA_LRIG2 is 2 kb upstream 
of the promotor region of both transcripts, but is within the first intron of LRIG2-DT. It has been 
demonstrated that intronic SVAs are associated with intron retention in mRNA [27,38], which may 
trigger various nuclear degradation mechanisms and result in decreased overall transcript levels [39]. 
Taken together, these results suggest that recent SVA insertion events may have the potential to 
fine-tune the expression of nearby transcripts, and that one potential mechanism for this is via 
modulation of methylation at the promoter region. These in situ observations expand upon previous 
work demonstrating the in vitro regulatory effects of SVAs [15,24]. This is pertinent when we 
consider that over 60% of SVAs are found in genes or within 10 kb of a gene [15], and may therefore 
influence a wide variety of biological processes. Given that the data presented here were derived 
from the NABEC cohort, our findings are specifically applicable to neurologically normal fontal 
cortex. Our observations therefore complement previous hypotheses that SVAs may be important 
sources of genomic variation in the central nervous system. As hominid-specific elements, SVAs may 
be implicated in the development of higher cognitive function and ongoing human-specific genome 
evolution [32]. It is also conceivable that transposable elements, particularly SVAs, which are 
currently filtered out of short-read WGS data represent an under-appreciated source of variation that 
may be relevant to genetically complex processes. This may be especially true for very recent, human-
specific insertion events and human-specific physiology and evolution. We note that short-read 
sequencing technology produces reads of up to 600 bases, with inherent difficulties in mapping 
repetitive elements back to the genome. By contrast, ‘long-read’ sequencing regularly generates reads 
of over 10 kb [40], meaning large or repetitive structural variants such as retrotransposons may be 
readily detected in WGS. Indeed, recent advances and decreasing costs of long-read sequencing 
technologies should soon make its implementation routine [41]. In light of the work presented here, 
we expect that improved detection of retrotransposons in WGS projects will inevitably lead to greater 
emphasis on their roles as important structural variants in the immediate future of human genomics 
research. 
4. Materials and Methods 
DNA samples from the NABEC cohort (dbGaP accession phs001300.v1.p1) underwent PCR with 
0.02 U/µl KOD Hotstart polymerase (Merck 71086, Darmstadt, Germany) and 1.5 mM MgSO4, 0.2 mM 
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dNTPs, 1 M betaine, and 0.3 µM of each primer. To amplify SVA_LRIG2 and its flanking regions, the 
forward primer used was 5′-TCCACGGACTTCCTAGAACG-3′ and the reverse primer used was 5′-
CGAGATGGCGGCAGTACC-3′. Thermal cycling conditions were 95 °C for 2 min, followed by 35 
cycles of 95 °C for 20 s, 58 °C for 10 s and 70 °C for 1 min 50 s. Samples then underwent agarose gel 
electrophoresis at 110 V for 90 min and were visualised on a BioDoc-It™ UV transilluminator (Analytik 
Jena: UVP, Upland, CA, US). 
In order to accurately capture the full genetic diversity of SVA_LRIG2, proxy SNPs were 
generated using the ‘--show-tags’ option in PLINK v1.90 [42] for each of the 4 SVA_LRIG2 VNTR 
region length variants observed in the 96 NABEC individuals validated in our lab (genotyping data 
not shown). For each variant, the proxy SNP with the highest r2 and D’ values was selected: VNTR 1 
proxy rs114767321, r2 = 1, D’ = 1; VNTR 2 proxy rs183751190, r2 = 1, D’ = 1; VNTR 3 proxy rs12744009, 
r2 = 0.894, D’ = 1. Proxy SNPs for VNTR variant 4 were excluded after filtering for genotype 
missingness (<0.1). The remaining proxy SNPs for SVA_LRIG2 variants were then grouped into RIP 
genotypes: −/−, +/− or +/+. 
Generation of the NABEC frontal cortex total RNA-seq data and CpG methylation data has been 
previously described in detail by Gibbs et al. [43]. Data relating to individuals under the age of 15 
were excluded to minimize developmental effects in the data. Expression data were extracted for 
LRIG2 and LRIG2-DT with Ensembl accession numbers ENSG00000198799.12 and 
ENSG00000238198.2, respectively. CpG data samples with sex mismatch were excluded. We noted 
that Illumina’s Infinium MethylationEPIC manifest file listed cg23932873 as containing the SNP 
rs61818193 with MAF = 0.5, which would be a potential confounder of this association analysis. 
However, rs61818193 does not have a frequency listed on dbSNP and was absent in pre-filtered WGS 
data in the NABEC cohort. Therefore, we concluded it was acceptable to proceed with use of this 
methylation probe as an mQTL readout. 
The CpG probes analysed at the LRIG2 locus were: cg13503476, cg23932873, cg22598841, 
cg16709384, cg26091510, cg04139429, cg23175215, cg17310611, cg24448849, cg15031996, cg10983720, 
cg14912723, cg21504385, cg09332974, and cg23961141. 
Linear regression analyses were performed in RStudio Version 1.2.1335 (Boston, MA, USA) 
using the ‘lm’ and ‘summary’ functions, where test statistics follow a Student’s t distribution. When 
assessing effects of SVA_LRIG2 genotype in RNA-seq and CpG methylation data for NABEC 
individuals, a total of 17 tests were performed: 2 RNA transcripts (LRIG2 and LRIG2-DT) and 15 CpG 
probes were examined. The 0.05 alpha significance level for these linear regression analyses was 
therefore adjusted using Bonferroni correction for multiple tests: 0.05/17 = 2.94E-3. 
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NABEC North American Brain Expression Consortium 
SVA SINE-VNTR-Alu 
RIP Retrotransposon insertion polymorphism 
LTR Long terminal repeat 
Hg38 Human genome assembly GRCh38 
VNTR Variable number tandem repeat 
SINE Short interspersed nuclear element 
SNP Single-nucleotide polymorphism 
CTCF CCCTC-binding factor 
CTCFL CTCF like 
LRIG2 Leucine-rich repeats and immunoglobulin-like domains 2 
dbRIP Database of RIPs in humans 
dbGaP Database of Genotypes and Phenotypes 
WGS Whole-genome sequencing 
TPM Transcripts per kilobase million 
mQTL Methylation quantitative trait loci 
SE Standard error 
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